DBVT — DBV Technologies S.A.
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: FR
- Exchange: NASDAQ Global Select
- Employees: 106
- Website: https://www.dbv-technologies.com
Latest SEC filings for DBVT
- S-3ASR — 2026-07-27
- 8-K — 2026-07-16
- 10-Q — 2026-07-16
- 8-K — 2026-06-29
- 8-K — 2026-06-05
- 8-K — 2026-05-05
- 8-K — 2026-04-30
- 10-Q — 2026-04-30
- 10-K/A — 2026-04-30
- 8-K — 2026-03-26
Latest DBVT news
- — DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans. (GlobeNewswire Inc.)
- — DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years (globenewswire.com)
- — DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis
Educational tool only — not investment advice.